N-(4'-hydroxy-biphenyl-2-yl)-acetamide | 106477-52-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4'-hydroxy-biphenyl-2-yl)-acetamide
• 英文别名: N-(4'-Hydroxy-biphenyl-2-yl)-acetamid；2'-Acetylamino-biphenyl-4-ol；Acetamide, N-(4'-hydroxy(1,1'-biphenyl)-2-yl)-；N-[2-(4-hydroxyphenyl)phenyl]acetamide
• CAS: 106477-52-5
• 化学式: C₁₄H₁₃NO₂
• 分子量: 227.263
• InChiKey: BAKMMIMFOBZRHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4'-hydroxy-biphenyl-2-yl)-acetamide 在 三氯氧磷 作用下， 生成 8-methoxy-6-methylphenanthridine
  参考文献：
  名称：

  68. N-杂环系列的潜在锥虫病。第三部分 烷氧基和羟基菲啶鎓盐

  摘要：

  DOI：

  10.1039/jr9500000311
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 N-(4'-hydroxy-biphenyl-2-yl)-acetamide
  参考文献：
  名称：

  68. N-杂环系列的潜在锥虫病。第三部分 烷氧基和羟基菲啶鎓盐

  摘要：

  DOI：

  10.1039/jr9500000311

文献信息

• Inhibitors of dihydroceramide desaturase for treating disease
  申请人：Centaurus Therapeutics

  公开号：US11135207B2

  公开（公告）日：2021-10-05

  Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

  本公开涉及二氢神经酰胺脱饱和酶1（Des1）抑制剂化合物和组合物，这些化合物和组合物在治疗某些疾病（例如代谢性疾病、心血管疾病、纤维化疾病、自身免疫性疾病/慢性炎症性疾病、囊性纤维化、多种癌症、神经退行性疾病、脂质沉积障碍及缺血/再灌注损伤）时是有用的，且预期对于患者而言Des1的抑制具有治疗作用。本发明还提供了抑制人类或动物受试者Des1活性的方法。
• Synthesis of Heterocyclic Compounds from Aryl Azides. IV. Benzo-, Methoxy-, and Chloro-carbazoles^1,2
  作者：PETER A. S. SMITH、JOHN M. CLEGG、J. H. HALL

  DOI：10.1021/jo01098a006

  日期：1958.4
• INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE
  申请人：Centaurus Therapeutics

  公开号：US20190328720A1

  公开（公告）日：2019-10-31

  Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.
• 68. Potential trypanocides of the N-heterocyclic series. Part III. Alkoxy- and hydroxy-phenanthridinium salts
  作者：F. C. Copp、L. P. Walls

  DOI：10.1039/jr9500000311

  日期：——